Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • BIOBUSINESS BRIEFS

Top companies and drugs by sales in 2019

  1. Lisa Urquhart

    1. Evaluate Vantage, London, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Roche is back on top. Over the past few years, the tussle for biopharma’s biggest company by sales has largely been contested by Novartis and Pfizer; but a winning streak of blockbuster launches, including the multiple sclerosis drug Ocrevus (ocrelizumab) and PD-L1 inhibitor Tecentriq (atezolizumab) have helped the Swiss group leapfrog both of its rivals to claim the number one spot in 2019 (Fig. 1a). The company was also assisted by the limited impact of biosimilar competition in the key US market for some of its previous biggest cash cows, including the cancer therapies Avastin (bevacizumab) and Herceptin (trastuzumab).

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Nature Reviews Drug Discovery 19, 228 (2020)

doi: https://doi.org/10.1038/d41573-020-00047-7

Competing Interests

The author declares no competing interests.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links